Idorsia (OTCMKTS:IDRSF) Shares Down 5.4% – Here’s Why

Idorsia Ltd (OTCMKTS:IDRSF)’s share price dropped 5.4% during mid-day trading on Thursday. The stock traded as low as $5.30 and last traded at $5.30. 200 shares changed hands during trading, a decline of 98% from the average session volume of 9,700 shares. The stock had previously closed at $5.60.

Analysts Set New Price Targets

A number of equities research analysts recently commented on IDRSF shares. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Idorsia in a research report on Monday, August 3rd. HC Wainwright reiterated a “buy” rating on shares of Idorsia in a research note on Monday, September 14th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

Idorsia Price Performance

The company’s 50 day simple moving average is $7.00 and its 200 day simple moving average is $5.96.

Idorsia Company Profile

Idorsia Ltd. is a biopharmaceutical company headquartered in Allschwil, Switzerland. The company was established in 2017 following the acquisition of Actelion by Johnson & Johnson, with Idorsia retaining Actelion’s research and development operations and a portfolio of pharmaceutical assets.

Idorsia discovers and develops medicines for conditions with significant unmet medical needs, focusing primarily on cardiovascular disease, central nervous system disorders, immunology and rare diseases.